硫福拉通过KEAP1-NRF2通路激活和减弱炎症信号来增强抗氧化剂防御来缓解牛皮
Chujun Ma1,2, Chaode Gu3, Panpan Lian3
1Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, PR China.
Cell death & disease
|November 25, 2023
概括
硫黄 (SFN) 通过减少炎症,有效治疗牛皮症状. 这项研究揭示了SFN.
科学领域:
- 皮肤病学和免疫学
- 分子生物学和药理学 分子生物学和药理学
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,影响全球数百万人.
- 硫福拉 (SFN) 是一种天然化合物,具有已知的抗炎和抗氧化特性.
研究的目的:
- 为了研究SFN的治疗效果,在一只因伊米基莫德诱导的牛皮的小鼠模型上.
- 阐明SFN在牛皮中的作用的潜在分子机制.
主要方法:
- 使用一种因米基莫德 (IMQ) 诱导的牛皮小鼠模型.
- 施用了SFN并评估了牛皮症状的严重程度 (红斑,,厚度).
- 进行了组织病理学分析,免疫组织化学,体外细胞研究 (HaCaT) 和网络药理学.
主要成果:
- SFN治疗显著改善了牛皮的症状,并减少了角质细胞标志物 (K16,K17,Ki67).
- SFN抑制了炎症通路 (STAT3,NF-κB) 和促炎细胞因子 (IL-1β,IL-6,CCL2).
- SFN激活了KEAP1-NRF2通路,这对其保护作用至关重要,NRF2缺乏的小鼠研究证明了这一点.
结论:
- 通过减轻炎症和异常的角质细胞增殖,SFN对牛皮具有显著的治疗潜力.
- KEAP1-NRF2通路被确定为SFN在牛皮的有益作用的关键分子标.
- SFN代表了一种有前途的治疗药物用于牛皮治疗.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.3K
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
464
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
499
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
499
